SavedAdd your journal

Journals / Turkish Journal of Hematology / 2009 / Cilt: 26 - Sayı: 3

Hemoglobin S hastalığının gen tedavisinde U7 snRNA kullanımı uygun mu?

Usage of U7 snRNA in gene therapy of hemoglobin S disorder - is it feasible?

Viröj WIWANITKIT
Pages
159–159
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

RESULTS: : According to this study, the analytical results show that fully recovery of hemoglobin in both function and biological process can be got.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE: OBJECTIVE: Hemoglobin (Hb) S disorder [beta6(A3)Glu-->Val, GAG >GTG] is an important hemoglobinopathy with the highest endemicity in Africa.
📊
Key Findings & Data:METHODS: METHODS: Here, the author performs a basic bioinformatics gene ontology study to assess the effect of co-expression between nucleic acid sequence for human Hb S beta globin chain and U7.623.
💡
Conclusion & Impact:RESULTS: : According to this study, the analytical results show that fully recovery of hemoglobin in both function and biological process can be got.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Hemoglobin · orak · RNA

Abstract

OBJECTIVE: OBJECTIVE: Hemoglobin (Hb) S disorder [beta6(A3)Glu-->Val, GAG >GTG] is an important hemoglobinopathy with the highest endemicity in Africa. METHODS: METHODS: Here, the author performs a basic bioinformatics gene ontology study to assess the effect of co-expression between nucleic acid sequence for human Hb S beta globin chain and U7.623. RESULTS: : According to this study, the analytical results show that fully recovery of hemoglobin in both function and biological process can be got. CONCLUSION: CONCLUSION: Here, the author proposed that U7 snRNA might be a probable tool for treatment by gene therapy approach in Hb S disorder.

Özet

OBJECTIVE: OBJECTIVE: Hemoglobin (Hb) S disorder [beta6(A3)Glu-->Val, GAG >GTG] is an important hemoglobinopathy with the highest endemicity in Africa. METHODS: METHODS: Here, the author performs a basic bioinformatics gene ontology study to assess the effect of co-expression between nucleic acid sequence for human Hb S beta globin chain and U7.623. RESULTS: : According to this study, the analytical results show that fully recovery of hemoglobin in both function and biological process can be got. CONCLUSION: CONCLUSION: Here, the author proposed that U7 snRNA might be a probable tool for treatment by gene therapy approach in Hb S disorder.

🔖

Cite This Article

WIWANITKIT, V. (2009). Hemoglobin S hastalığının gen tedavisinde U7 snRNA kullanımı uygun mu?. Turkish Journal of Hematology, Cilt: 26 - Sayı: 3, 159–159. https://ajindex.com/articles/413195

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (7)

  1. Schnog JB, Duits AJ, Muskiet FA, ten Cate H, Rojer RA, Brandjes DP.Sickle cell disease; a general overview. Neth J Med. 2004;62:364-74
  2. Gorman L, Kole R. Gene therapy approaches to the treatment of hemoglobinopathies. Gene Ther Mol Biol 1999;3:189-96
  3. Khan S, Situ G, Decker K, Schmidt CJ. GoFigure: automated Gene Ontology annotation. Bioinformatics 2003;19:2484-5 4. Phillips SC, Turner PC. Nucleotide sequence of the mouse U7 snRNA gene. Nucleic Acids Res 1991;19:1344
  4. Wiwanitkit V. Usage of U7 snRNA in gene therapy of hemoglobin C disorder: feasibility by gene ontology tool. African J Biotechnol. 2007;6:683-4
  5. Gorman L, Suter D, Emerick V, Schumperli D, Kole R. Stable alteration of pre-mRNA splicing patterns by modified U7 small nuclear RNAs. Proc Natl Acad Sci U S A 1998;95:4929-34
  6. Suter D, Tomasini R, Reber U, Gorman L, Kole R, Schumperli D. Double-target antisense U7 snRNAs promote efficient skipping of an aberrant exon in three human b-thalassemic mutations. Human Mol Genet 1999;8:2415-23
  7. Suwanmanee T, Sierakowska H, Fucharoen S, Kole R. Repair of a splicing defect in erythroid cells from patients with b-thalassemia/ HbE disorder. Mol Ther 2002;6:718-26.